About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT04061395

Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.

This is a multicenter open-label mode of action study. Twenty patients with moderate to severe hidradenitis suppurativa will be treated with guselkumab 200 mg Q4W subcutaneously. Main objectie is to i...

Lead sponsor: University Medical Center Groningen•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Medical Center Groningen

Collaborators

Janssen-Cilag Ltd.

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•moderate to severe HS
•treatment history of at least one systemic anti-inﬂammatory / immunosuppressive agent;
•HS diagnosis of at least 1 year;
•minimum of two anatomical locations with HS lesions
•minimum of 4 active abscesses and/or inflammatory nodules (AN).

Exclusion Criteria

•contra-indication for guselkumab;
•previous use of guselkumab;
•use of treatment with biologics or any immunosuppressives for HS in the last 3 months prior to randomization;
•presence of other uncontrolled major disease;
•pregnant or lactating women

Related studies

Clinical and Biological Characteristics of Hidradenitis Suppurativa

NCT03967600 · Hidradenitis Suppurativa

RECRUITINGPhase 3

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

NCT06959225 · Hidradenitis Suppurativa

RECRUITINGPhase 3

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

NCT06958211 · Hidradenitis Suppurativa

RECRUITINGPhase 1

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

NCT07049575 · Hidradenitis Suppurativa

RECRUITINGPhase 3

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

NCT06921850 · Hidradenitis Suppurativa

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 5, 2024Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment20

Start dateOct 2019

Last updatedApr 5, 2024

Condition

Hidradenitis Suppurativa

Locations shown

Erasmus MC, University Medical Center Rotterdam

Rotterdam, South Holland

University Medical Center Groningen

Groningen

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 5, 2024Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions